AOD-9604
Also called Tyr-hGH 177-191.
AOD-9604 has no FDA-approved product. This page cites 2 sources, and the strongest evidence comes from human trials.
- Status
- No FDA-approved product
- Form
- Tablet
- Half-life
- Not modeled
- Strongest evidence
- Human trials
- Cited claims
- 1
- Last updated
- November 6, 2026
What the evidence says
Each claim names the kind of study behind it, what it can't tell you, and where it comes from.
Human trials
The randomized OPTIONS obesity trial enrolled 536 adults and randomized 502. Oral AOD-9604 did not produce significantly greater weight loss than placebo at the 12-week primary endpoint.
Limits: Treatment lasted 24 weeks alongside diet and exercise. FDA reports the negative result from sponsor disclosures; the published trial report emphasizes safety. These data do not establish weight-loss efficacy or validate subcutaneous products.
Regulatory status
United States
There is no FDA-approved AOD-9604 drug. FDA evaluated the free base and acetate for obesity and found insufficient evidence of effectiveness. Its assessment did not establish subcutaneous efficacy or long-term safety. Compounding discussions do not establish approval or a validated treatment regimen.